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Objective: 5′-adenosine monophosphate-activated protein kinase (AMPK) is a key 
molecule of metabolic enhancement in skeletal muscle. We investigated whether 
metformin (MET) acts directly on skeletal muscle, is transported into skeletal muscle 
via organic cation transporters (OCTs), and activates AMPK. 
Materials/Methods: Isolated rat epitrochlearis and soleus muscles were incubated in 
vitro either in the absence or in the presence of MET. The activation status of AMPK, 
the intracellular energy status, and glucose and MET transport activity were then 
evaluated. The effect of cimetidine, which is an OCT inhibitor, on AMPK activation was 
also examined. 
Results: MET (10 mmol/L, ≥ 60 min) increased the phosphorylation of Thr172 at the 
catalytic α subunit of AMPK in both muscles. AMPK activity assays showed that both 
AMPKα1 and AMPKα2 activity increased significantly. The AMPK activation was 
associated with energy deprivation, which was estimated from the ATP, 
phosphocreatine (PCr), and glycogen content, and with increased rates of 
3-O-methyl-D-glucose (3MG) transport. MET did not change the basal phosphorylation 
status of insulin receptor signaling molecules. MET was transported into the cytoplasm 
in a time-dependent manner, and cimetidine suppressed MET-induced AMPK 
phosphorylation and 3MG transport. 
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 Conclusion: These results suggest that MET is acutely transported into skeletal muscle 
by OCTs, and stimulates AMPKα1 and α2 activity in both fast- and slow-twitch muscle 
types, at least in part by reducing the energy state. 
 
Keywords: Metformin, 5′-adenosine monophosphate-activated protein kinase, Organic 
cation transporter, Glucose transport, Skeletal muscle  
Abbreviations: MET, metformin; AMPK, 5′-adenosine monophosphate-activated protein 
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 1. Introduction 
 
Metformin (MET) is the most commonly prescribed medication in the world for 
type 2 diabetes mellitus (T2DM) patients, and treatment with MET has reduced the 
incidence of T2DM in the Diabetes Prevention Program [1]. MET is known to lower the 
blood glucose level mainly through hepatic glucose output as a result of increased 
hepatic insulin sensitivity [2]. The molecular mechanism of MET action is not fully 
understood, but Zhou et al. [3] demonstrated in 2001 that MET stimulates the 
“metabolic regulator” 5′-adenosine monophosphate-activated protein kinase (AMPK) 
with decreased glucose production in primary cultured rat hepatocytes. Since then, a 
number of studies have documented MET activation of hepatic AMPK. However, 
although skeletal muscle has been implicated in the antidiabetic effect of MET [2], only 
a few studies have examined skeletal muscle AMPK. Zhou et al. [3] found that MET (2 
mmol/L, 3 h) stimulated AMPKα1 and α2 activity and glucose transport in isolated rat 
fast-twitch epitrochlearis muscle, but the effects of MET on slow-twitch muscle and on 
muscle energy status were not examined. Musi et al. [4] showed that 10 weeks of MET 
treatment increased AMPKα2 activity and decreased ATP, phosphocreatine (PCr), and 
glycogen content in vastus lateralis muscle biopsies from T2DM patients, but neither 
the acute effect of MET administration on AMPK nor the energy status was studied. 
Suwa et al. [5] and Kristensen et al. [6] showed that a single oral dose of MET promoted 
AMPK phosphorylation in multiple muscle types in rats [5] and mice [6], but they did 
not examine AMPK activity or energy status. Furthermore, Kristensen et al. [6] did not 
detect any increase in glucose transport in skeletal muscles. 
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 MET has been identified as a substrate of organic cation transporters (OCTs). 
MET uptake in the liver is mediated by OCT1 [7-9], and deletion of Oct1 decreased both 
MET-stimulated AMPK phosphorylation and inhibition of glucose production in mouse 
hepatocytes [8]. Moreover, reduced-function alleles of OCT1 have been associated with a 
reduction in the effect of MET on the oral glucose tolerance test in humans [8]. On the 
other hand, skeletal muscle expresses OCT1 and OCT3 [10, 11], and the general OCT 
inhibitor cimetidine was reported to block MET-stimulated AMPK phosphorylation in 
primary cultured human skeletal muscle cells [11]. However, to our knowledge, no study 
has tested the ability of mature skeletal muscle to take up MET into the cytoplasm. 
We conducted this study to reevaluate the hypothesis that MET acts directly on 
different muscle types, and that it can activate both AMPK and glucose transport under 
reduced energy status. We also examined the possibility that MET is acutely 




 2. Materials and Methods 
 
2.1. Animals 
Male Wistar rats aged 5 weeks (Shimizu Breeding Laboratories, Kyoto, Japan) 
were fed a standard chow and water ad libitum. The animals were randomly divided 
into the experimental groups after an overnight fast. Experimental protocols were 
approved by Kyoto University Graduate School of Human and Environmental Studies, 
and Kyoto University Radioisotope Research Center. 
 
2.2. Muscle treatment in vivo 
Rats were injected with MET (250 mg/kg body wt) dissolved in saline into the 
peritoneal cavity without anesthesia. The volume of injection was 10 ml/kg body wt. 
Control rats were injected with saline. Forty five minutes after MET or saline injection, 
rats were anesthetized with injection of 40 mg/kg pentobarbital sodium into the 
peritoneal cavity. Fifteen minutes after anesthesia the blood glucose level was measured 
from the cut tail tip using Glutest-Ace (Sanwa Kagaku Kenkyusho, Nagoya, Japan). 
Then the fast-twitch epitrochlearis muscle [12] and slow-twitch soleus muscle [13] were 
rapidly isolated and frozen in liquid nitrogen. The muscles were then assayed for 
isoform-specific AMPK activity. 
 
2.3. Muscle preparation in vitro 
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 Muscle incubation was performed as we previously described [14]. 
Epitrochlearis and soleus muscles were isolated immediately after cervical dislocation. 
The muscles were then attached to an incubation apparatus, and preincubated in 
Krebs–Ringer bicarbonate buffer (KRB) containing 2 mmol/L pyruvate for 40 min. The 
muscles were transferred to fresh buffer either in the absence or presence of 2 or 10 
mmol/L MET for up to 120 min. The muscles were also incubated in fresh buffer 
containing 0.5 mmol/L 2,4-dinitrophenol (DNP) for 15 min or 2 mmol/L 
5-aminoimidazole-4-carboxamide-1-α-D-ribonucleoside (AICAR) for 30 min for maximal 
stimulation of AMPK, or 1 µmol/L insulin for 30 min for maximal stimulation of Akt. 
The OCT inhibitor cimetidine [11], when present, was added in the preincubation and 
incubation buffer. The concentration of dimethyl sulfoxide was 0.5%, which had no 
effect in any assay. The muscles were either used for MET transport and glucose 
transport measurements, or frozen in liquid nitrogen for subsequent analysis. Some 
muscles, liver, kidney, and heart were frozen after dissection for Western blotting of 
OCTs. 
 
2.4. Western blotting 
Western blotting was conducted as we previously described [14]. Frozen 
muscles were homogenized in homogenization buffer containing 1% Triton X-100, 20 
mmol/L Tris·HCl (pH 7.4), 250 mmol/L sucrose, 50 mmol/L NaCl, 2 mmol/L 
dithiothreitol, 50 mmol/L NaF, 5 mmol/L sodium pyrophosphate, 50 mg/L trypsin 
inhibitor, 4 mg/L leupeptin, 0.1 mmol/L benzamidine, and 0.5 mmol/L 
phenylmethylsulfonyl fluoride at 4°C. The homogenate was centrifuged at 16,000 g for 
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 40 min at 4°C. Aliquots of the supernatant (15 µg protein) were separated by SDS-PAGE, 
transferred to polyvinylidene difluoride membranes. The membranes were blocked with 
skim milk, and then incubated overnight at 4°C with primary antibodies [AMPKα 
Thr172, AMPKα, acetyl CoA carboxylase (ACC), mammalian target of rapamycin 
(mTOR) Ser2448, mTOR, p70 ribosomal protein S6 kinase (p70S6K) Thr389, p70S6K, 
eukaryotic initiation factor 4-binding protein 1 (4E-BP1) Thr37/46, 4E-BP1, Akt Ser473, 
Akt, glycogen synthase kinase (GSK)-3β Ser9, GSK-3β, actin (Cell Signaling Technology, 
Danvers, MA), insulin receptor substrate (IRS)-1 Tyr612 (Life Technologies, Carlsbad, 
CA), ACC Ser79, IRS-1 (Millipore, Billerica, MA), GLUT4 glucose transporter 
(Biogenesis, Poole, UK), OCT1, OCT2, OCT3 (Santa Cruz Biotechnology, CA)]. The 
membranes were then incubated with anti-rabbit IgG or anti-goat IgG. Protein signals 
were developed using enhanced chemiluminescence (Millipore) and detected with 
ImageCapture G3 (Liponics, Tokyo, Japan).  
 
2.5. Isoform-specific AMPK activity assay 
Skeletal muscle expresses two catalytic subunits of AMPK, α1 and α2 [15]. The 
α-isoform-specific kinase activity was determined as we previously described [14]. 
Frozen muscles were homogenized as described in “Western blotting.” The supernatant 
(100 µg protein) was incubated with either anti-AMPKα1 or α2 antibody and Protein A 
Sepharose beads (Amersham Biosciences, Uppsala, Sweden) at 4 °C overnight. The 
beads were then subjected to kinase reaction using the SAMS peptide as substrate. The 





2.6. MET transport and glucose transport assay 
The MET transport was measured using the double-isotope ([14C]MET and 
D-[1-3H(N)]mannitol) method. Muscles were preincubated, and incubated in KRB 
containing 10 mmol/L [14C]MET (0.3 µCi/ml, American Radiolabeled Chemicals, St. 
Louis, MO) and 1 mmol/L D-[1-3H(N)]mannitol (1.5 µCi/ml, American Radiolabeled 
Chemicals) at 37°C for up to 60 min. Muscles were then digested in 1 mol/L NaOH at 
80°C for 10 min. Digestates were neutralized with 1 mol/L HCl and centrifuged at 
20,000 g for 3 min, and radioactivity in aliquots of supernatant was measured by a 
scintillation counter. The intracellular space was determined as described [16], and the 
intracellular MET concentration was calculated. The 3-O-methyl-D-glucose (3MG) 
transport was also measured using the double-isotope ([3H]3MG and D-[1-14C]mannitol) 
method, as we previously described [14]. The transport activity was expressed as 3MG 
taken up per intracellular space per hour. 
 
2.7. ATP, PCr, and glycogen assay 
ATP and PCr contents were measured enzymatically as we previously 
described [17]. Glycogen content was measured using a glucose assay reagent (Glucose 
CII Test , Wako, Osaka, Japan) as described previously [18]. 
 
2.8. Statistical analysis 
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 Data are expressed as mean ± standard error (SE). Differences between two 
groups were compared with Student’s t-test. Multiple means were analyzed using 
one-way ANOVA followed by post hoc comparison with Tukey’s test. P < 0.05 was 




 3. Results 
 
3.1. Intraperitoneal MET administration increases AMPKα1 and α2 activity in rat 
skeletal muscles 
To confirm that MET acutely increases AMPK activity in vivo, 
α-isoform-specific AMPK activity was measured 60 min after intraperitoneal injection 
of either MET (250 mg/kg) or saline. MET increased AMPKα1 activity by 1.2- and 
1.6-fold and AMPKα2 activity by 1.4- and 1.3-fold in epitrochlearis (Fig. 1A) and soleus 
(Fig. 1B) muscles, respectively. Blood glucose levels 60 min after MET injection (2.8 ± 
0.1 mmol/L, n=6) were significantly lower than those after saline injection (4.7 ± 0.2 
mmol/L, n=7, P < 0.001 vs. MET group). 
 
3.2. MET promotes AMPKα Thr172 phosphorylation and stimulates both AMPK α1 and 
α2 activity in isolated rat skeletal muscles 
To verify that MET acts directly on skeletal muscle, isolated muscles were 
incubated in vitro to avoid confounding effects of humoral, circulatory, gastrointestinal, 
and neuronal factors. The time-course data revealed that phosphorylation of AMPKα 
Thr172 increased 60 and 120 min after exposure to 10 mmol/L MET in epitrochlearis (Fig. 
2A) and soleus (Fig. 2B) muscles, respectively. The total amount of AMPK did not 
change during the study. The dose–response data showed that 2 mmol/L MET did not 
significantly promote phosphorylation of AMPKα Thr172 (data not shown). The 
α-isoform-specific AMPK activity assay showed that MET (10 mmol/L, 120 min) 
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 increased AMPKα1 activity by 4.3- and 3.4-fold, and AMPKα2 activity by 1.6- and 
2.9-fold in epitrochlearis (Fig. 2C) and soleus (Fig. 2D) muscles, respectively. The 
increase of AMPKα1 activity was significantly greater than that of AMPKα2 in 
epitrochlearis muscle (P < 0.001) (Fig. 2C). MET (10 mmol/L, 120 min) also increased 
the extent of phosphorylation of ACC Ser79 in epitrochlearis (Fig. 2E) and soleus (Fig. 
2F) muscles. The phosphorylation of ACC Ser79 reflects the extent of intracellular 
activation of AMPK in skeletal muscle [19, 20]. Known AMPK activators DNP and 
AICAR elicited moderate to robust phosphorylation of AMPK and ACC (Figs. 2E and 
2F). 
 
3.3. MET is transported into isolated rat skeletal muscles via OCTs 
To our knowledge, no study has shown that MET is transported into skeletal 
muscle. We examined the OCT protein expression levels by Western blot analysis, and 
clearly detected OCT1 and OCT3 protein in epitrochlearis, soleus, and fast-twitch 
extensor digitorum longus (EDL) muscles (Fig. 3A). In contrast, OCT2 protein was not 
detectable in any of the muscle types (data not shown), which is consistent with 
previous studies showing no detectable expression of OCT2 in skeletal muscle [10, 11]. 
We found that MET was taken up into both epitrochlearis (Fig. 3B) and soleus (Fig. 3C) 
muscles in a time-dependent manner. Furthermore, simultaneous incubation with 
cimetidine suppressed the MET-induced phosphorylation of AMPKα Thr172 in 
epitrochlearis (Fig. 3D) and soleus (Fig. 3E) muscles. The total amount of AMPK did not 




3.4. MET decreases energy status and stimulates glucose transport in isolated rat 
skeletal muscles 
AMPK is implicated in the mechanism of insulin-independent glucose 
transport, which is elicited by energy-depriving stimuli including hypoxia, inhibition of 
oxidative phosphorylation, and contraction [21, 22]. MET inhibits complex 1 of the 
mitochondrial respiratory chain and impairs oxidative phosphorylation [23, 24]. To 
determine the energy status of skeletal muscle, we measured ATP, PCr, and glycogen 
content. MET (10 mmol/L, 120 min) significantly decreased these parameters in both 
epitrochlearis and soleus muscles (Table 1). Correspondingly, MET (10 mmol/L, 120 
min) increased 3MG transport activity 2.4- and 1.7-fold above the basal level in 
epitrochlearis (Fig. 4A) and soleus (Fig. 4B) muscles, respectively. In parallel with the 
MET-induced AMPK phosphorylation (Figs. 3D and 3E), MET-induced 3MG transport 
activity was suppressed by cimetidine in both epitrochlearis (Fig. 4A) and soleus (Fig. 
4B) muscles. 
 
3.5. MET does not affect insulin receptor signaling molecules in isolated rat skeletal 
muscles 
We examined whether MET affects the activation status of insulin receptor 
signaling molecules in skeletal muscle. Similar to the known AMPK activators (DNP, 
AICAR), MET (2 mmol/L, 120 min) did not change the phosphorylation of IRS-1, Akt, 
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 GSK-3β, mTOR, p70S6K, or 4E-BP1 in either epitrochlearis (Fig. 5A) or soleus (Fig. 5B) 




 4. Discussion 
 
Growing evidence suggests that AMPK is involved in acute and chronic 
metabolic activation processes in skeletal muscle, such as insulin-independent glucose 
transport, fatty acid oxidation, glycogen regulation, expression of glucose transporter 
GLUT4, activation of peroxisome proliferator-activated receptor γ coactivator 1α, 
mitochondrial biogenesis, and enhanced insulin sensitivity [25, 26]. Exercise (muscle 
contraction) is a strong activator of AMPK in skeletal muscle, but recent reports suggest 
that there are a number of physiologically relevant stimuli of AMPK in skeletal muscle, 
such as adipokines including leptin and adiponectin, antidiabetic drugs such as MET 
and thiazolidinediones, and functional foods and their natural components [25, 27, 28]. 
In our earlier studies, we demonstrated that Morus alba leaf extract [29], caffeine [17], 
berberine [30], Coptidis rhizoma extract [31], and caffeic acid [32], all of which have 
been associated with antidiabetic properties, acutely (<30 min) stimulate AMPK 
activity in isolated rat skeletal muscles. 
We examined the effects of MET in different types of skeletal muscle. Bikman 
et al. [33] reported that chronic oral administration of MET for 4 weeks increased 
AMPK and ACC phosphorylation in glycolytic muscle (white gastrocnemius), but not in 
oxidative muscles (soleus and red gastrocnemius) in lean and obese Zucker rats. On the 
other hand, Kristensen et al. [6] showed that oral treatment with MET for 2 weeks 
induced significant metabolic activation (increased insulin-stimulated glucose 
transport) in soleus but not in EDL muscle in mice. In the present study, we found 
stimulation of AMPK that was not specific to muscle type, indicating that most skeletal 
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 muscles respond to MET in vivo. However, we found that MET elicits greater activation 
of AMPKα1 (by 4.3-fold) than AMPKα2 (by 1.6-fold) in isolated rat epitrochlearis muscle 
(Fig. 2C). Zhou et al. [3] also reported that MET treatment (2 mmol/L, 3 h) stimulated 
AMPKα1 activity (by approximately 2.5-fold) to a greater extent than AMPKα2 (by 
approximately 1.5-fold) in isolated rat epitrochlearis muscle. In contrast, MET 
increased AMPKα1 activity to a similar extent to that of AMPKα2 in soleus muscle (Fig. 
2D). Thus, the magnitude of the effect of MET may vary depending on the muscle type. 
We have found that the isolated skeletal muscle preparation is a useful tool 
with which to elucidate the actual effect of MET on AMPK. AMPKα2 activity accounts 
for the major part (70%–80%) of basal AMPK activity in rat skeletal muscle, with 
AMPKα1 making up the remaining 20%–30% [34]. The α2-isoform is also the major 
α-isoform in biopsied human vastus lateralis muscle [35]. Importantly, AMPK, with the 
α1 isoform in particular, is easily activated during dissection as a postmortem artifact 
[36]. Even when actual AMPK activity is increased in vivo, it may be exceeded by 
additional activation of AMPK during dissection. Therefore, sufficient preincubation is 
required to stabilize AMPK to the basal level [36]. It is also noteworthy that, in contrast 
to mature muscle, α1 is the predominant α-isoform, and α2 activity is minimal in 
cultured muscle cells including L6 [37]. 
The physiological significance of AMPKα1, the minor isoform in skeletal 
muscle, has been documented in contraction-stimulated glucose transport. Jensen et al. 
[38] investigated the impact of low-intensity contractions, and demonstrated that 
glucose transport was activated in soleus muscle of AMPKα2-knockout mice but not in 
soleus muscle of AMPKα1-knockout and AMPK kinase-dead (KD) mice. Jørgensen et al. 
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 [39] investigated high-intensity contractions, and showed that glucose transport 
activity was significantly reduced in the soleus muscle of AMPKα1-knockout mouse. 
These observations indicate that AMPKα1 is relevant for the activation of glucose 
transport by low-intensity contractions, and is essential for additional activation of 
glucose transport by high-intensity contractions. The importance of AMPKα1 has also 
been suggested by our earlier studies, which showed that oxidative stress (H2O2, 
hypoxanthine/xanthine oxidase) [14], low-intensity contraction [36], and the presence of 
caffeine in low concentration (1 mmol/L) [40] increased AMPKα1 activity and 
insulin-independent glucose transport without AMPKα2 activation in isolated 
epitrochlearis muscle. 
We have recently reported that caffeine (3 mmol/L, 15 min) stimulated AMPK 
and also dephosphorylated insulin receptor signaling including IRS-1 (Tyr612), Akt 
(Ser473), and GSK3β (Ser9) in isolated rat epitrochlearis muscle [41]. In contrast, Morus 
alba leaf extract [29], berberine [30], and caffeic acid [32] acutely stimulated AMPK, but 
they did not affect Akt Ser473 phosphorylation in isolated rat epitrochlearis muscle. In 
the present study, MET did not change the phosphorylation status of insulin signaling 
molecules in either muscle type (Figs. 5A and B). MET may not have a modulatory effect 
on these molecules, at least in the absence of insulin and during the acute time period. 
We showed that MET is transported into skeletal muscle and that within 60 
min the concentration of MET was comparable with that of incubation buffer (10 
mmol/L) (Figs. 3B and C). It is notable that a typical clinical dose of MET is 1000–2000 
mg/day, and peak plasma concentrations of MET are about 3 mg/L (2.5 µmol/L) after an 
oral dose of 1000–1500 mg in humans [42]. Thus, it is unlikely that a single dose of MET 
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 is sufficient to provoke clinically relevant activation of AMPK in human skeletal muscle. 
As demonstrated by Musi et al. [4], who found significantly increased AMPKα2 activity 
and decreased ACC activity as well as reduced energy status in biopsied muscle samples 
from T2DM after 10-week treatment, long-term MET administration might be needed. 
Our data provide fundamental evidence that confirms the stimulatory actions 
of MET on AMPK signaling. MET acutely increased AMPKα Thr172 phosphorylation 
and the activities of both AMPKα1 and α2, in association with decreased ATP, PCr, and 
glycogen levels. The enhanced levels of phosphorylation of cellular substrate ACC and 
increased levels of glucose transport indicated a substantial activation of AMPK in vivo. 
MET was transported into the cytoplasm, and the stimulatory effects of AMPK 
phosphorylation and glucose transport were inhibited by cimetidine. All these effects 
occurred in both fast-twitch epitrochlearis and slow-twitch soleus muscles. In 
conclusion, we propose that MET is transported into skeletal muscle by OCTs, and that 
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 Figure and table legends 
 
Fig. 1  A single intraperitoneal injection of MET acutely increases AMPK activity in 
skeletal muscles. 
Epitrochlearis (A) and soleus (B) muscles were removed 60 min after MET (250 mg/kg) 
or saline administration. AMPK activity was measured in anti-α1 and anti-α2 
immunoprecipitates. Values are means ± SE; n=5–8. * P < 0.05 and *** P < 0.001 vs. 
control group. 
 
Fig. 2  MET activates AMPK in isolated skeletal muscles. 
Epitrochlearis (A) and soleus (B) muscles were incubated with MET (10 mmol/L) for 0 
(control), 15, 30, 60, or 120 min. The lysate was analyzed by Western blotting. The 
values are means ± SE; n=5–7. *P < 0.05 and **P < 0.01 vs. control. Epitrochlearis (C) 
and soleus (D) muscles were incubated in the absence (control) or presence of 10 mmol/L 
MET for 120 min. The lysate was subjected to α-isoform-specific AMPK activity assay. 
Values are means ± SE; n=13–21. ** P < 0.01 and *** P < 0.001 vs. control group. 
Epitrochlearis (E) and soleus (F) muscles were incubated in the absence (control) or 
presence of MET (10 mmol/L) for 120 min, AICAR (2 mmol/L) or insulin (1 µmol/L) for 
30 min, or DNP (0.5 mmol/L) for 15 min. The lysate was analyzed by Western blotting. 




 Fig. 3  MET is transported into isolated skeletal muscles, and the OCT inhibitor 
cimetidine suppresses MET-stimulated AMPK phosphorylation. 
(A) Epitrochlearis (EPI), soleus (SOL), and extensor digitorum longus (EDL) muscles 
were dissected and analyzed by Western blotting. Representative immunoblots are 
shown. Epitrochlearis (B) and soleus (C) muscles were incubated with 10 mmol/L MET 
for 30 or 60 min. Intracellular MET concentration was determined at each time point. 
Values are means ± SE; n=6–7. *** P < 0.001 vs. 0-min group. ### P < 0.001 vs. 30-min 
incubation group. Epitrochlearis (D) and soleus (E) muscles were incubated in the 
absence (control) or presence of 10 mmol/L MET for 120 min either with or without 
cimetidine (C: 0.1, 1.0, or 10 mmol/L). The lysate was analyzed by Western blotting. 
Representative immunoblots are shown. 
 
Fig. 4  The OCT inhibitor cimetidine suppresses MET-stimulated glucose transport 
activity in isolated skeletal muscles. 
Epitrochlearis (A) and soleus (B) muscles were incubated in the absence (control) or 
presence of 10 mmol/L MET for 120 min with or without cimetidine (C: 10 mmol/L), and 
the rate of 3MG transport was measured. Values are means ± SE; n=7–10. *** P < 0.001 
vs. control group. # P < 0.05 and ### P < 0.001 vs. MET group. 
 
Fig. 5  MET does not affect insulin signaling in isolated skeletal muscles. 
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 Epitrochlearis (A) and soleus (B) muscles were incubated in the absence (control) or 
presence of MET (10 mmol/L) for 120 min, DNP (0.5 mmol/L) for 15 min, or AICAR (2 
mmol/L) or insulin (1 µmol/L) for 30 min. The lysate was analyzed by Western blotting. 
Representative immunoblots are shown. 
 
Table 1 
ATP, PCr, and glycogen content in isolated skeletal muscles. Epitrochlearis (EPI) and 
soleus (SOL) muscles were incubated in the absence (control) or presence of 10 mmol/L 
MET for 120 min. ATP, PCr, and glycogen content were determined. Values are 
expressed as nanomoles per milligram wet weight. Values are means ± SE; n=6–13. * P 
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EPI ATP 6.50±0.38 4.34±0.45**
PCr 12.0±0.50 4.31±0.87***
Glycogen 19.2±1.62 7.34±1.22***
SOL ATP 1.65±0.11 1.13±0.20*
PCr 6.24±0.27 5.04±0.31**
Glycogen 15.2±0.56 13.6±0.60*
Table 1
